Citius Oncology, Inc. (CTOR)

Citius Oncology, Inc. is a biopharmaceutical company focused on cancer therapies and is majority-owned by Citius Pharmaceuticals. The company is based in Cranford, New Jersey.

Its lead product is LYMPHIR (denileukin diftitox), an engineered protein that combines a fragment of the diphtheria toxin with interleukin-2 to target cancer cells carrying the IL-2 receptor. LYMPHIR is approved in the United States for adult patients with relapsed or refractory cutaneous T-cell lymphoma, a rare type of non-Hodgkin lymphoma that affects the skin, after prior systemic therapy. Citius Oncology is responsible for commercializing LYMPHIR and is exploring its use in other cancers, including in combination with immunotherapies.